Patient outcomes of hydroxychloroquine as postexposure prophylaxis
13% of participants were either PCR confirmed or had compatible COVID-19 symptoms that developed during the 14 days follow up. There was not a significant difference between those that received hydroxychloroquine and those that received a placebo. P-value of 0.35 and an absolute difference of -2.4 percentage points.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Patient outcomes of hydroxychloroquine as postexposure prophylaxis
ACE2 Variation May Influence the Efficacy of Hydroxychloroquine or Chloroquine in Treating COVID-19
TMPRSS2 Variation May Influence the Efficacy of Hydroxychloroquine or Chloroquine in Treating COVID-19
Dosage of hydroxychloroquine as postexposure prophylaxis
Patient outcomes of hydroxychloroquine as postexposure prophylaxis
Sample of hydroxychloroquine as postexposure prophylaxis
Hydroxychloroquine as Pre-Exposure Prophylactic Treatment for COVID-19 Patients